Emergent BioSolutions (EBS) announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000 to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales for ACAM2000 vaccine and ancillary products to more than $120 million this year from a diverse base of customers. ACAM2000 is licensed for active immunization against smallpox and mpox disease for persons determined to be at high risk for smallpox or mpox infection.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Advances Pediatric Botulism Antitoxin Study
- Emergent BioSolutions Secures $30M BARDA Contract Extension
- Emergent BioSolutions awarded $30M contract modification for CYFENDUS
- LSBK, EBS, MNSO: Three AI Analyst Stocks With Over 20% Upside
- Emergent BioSolutions’ AIGIV Study: A Potential Game-Changer for Inhalational Anthrax Treatment